title: Quality of life and efficacy of nebivolol in an open-label study in hypertensive patients. the QoLaN study.
abstract: BACKGROUND
  Nebivolol is a highly selective beta-adrenoreceptor antagonist with vasodilating properties. This study investigated its effect on quality of life (QoL) and blood pressure (BP) in real life conditions. In total, 1468 patients were enrolled, 12% diabetics. Nebivolol was prescribed as monotherapy, add-on or switch medication.
  
  
  METHODS
  In this open-label, prospective study, the JNC-VII BP target values were used: < 140/90 and < 130/80 mmHg for diabetics. The responder rate and the QoL was determined at baseline and after 4 and 8 weeks.
  
  
  RESULTS
  After 4 weeks, 27% of subjects reached target BP, 45% after 8 weeks. The responder rates were 92, 90 and 83% for the monotherapy, add-on and switch groups. Compared with baseline, all showed statistical significance at 8 weeks. Similarly to results for the QoL after 8 weeks, the mean improvement in QoL for all three groups was 9-10 points (total range: 0-88).
  
  
  CONCLUSIONS
  The study demonstrates that nebivolol in mild to moderate hypertension is associated with overall improvements in QoL, with a marked BP-lowering effect, in monotherapy, add-on or switch, irrespective of the glucose tolerance status. It may be hypothesized that its dual mode of action explains its BP-lowering effect as well as the tolerability.
authors.affiliation: Department of endocrinology and Nutrition, St-Luc University Hospital, Catholic University of Louvain, Brussels, Belgium. michel.hermans@diab.ucl.ac.be
authors.forename: Michel P
authors.initials: MP
authors.lastname: Hermans
authors.forename: Olivier
authors.initials: O
authors.lastname: De Coster
authors.forename: Laurence
authors.initials: L
authors.lastname: Seidel
authors.forename: Adelin
authors.initials: A
authors.lastname: Albert
authors.forename: Philippe
authors.initials: P
authors.lastname: Van de Borne
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001578:Benzopyrans / Q000627:therapeutic use*; D003920:Diabetes Mellitus; D004983:Ethanolamines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D000068577:Nebivolol; D011446:Prospective Studies; D011788:Quality of Life
chemical_list: D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D001578:Benzopyrans; D004983:Ethanolamines; D000068577:Nebivolol